Grade 3 or 4 nonhematologic adverse events
| Events . | Subjects affected . | |
|---|---|---|
| Total n (%) . | Treatment-related, n (%) . | |
| Febrile neutropenia | 8 (22) | 4 (11) |
| Infection | 4 (11) | 1 (3) |
| Cardiac (arrhythmia, CHF, vasovagal) | 4 (11) | 1 (3) |
| Pulmonary (pneumonitis, pneumonia) | 4 (11) | 1 (3) |
| Constitutional symptoms | 4 (11) | 1 (3) |
| Dermatologic | 4 (11) | 0 (0) |
| Vascular access-related thrombosis | 2 (6) | 0 (0) |
| Hemorrhage | 2 (6) | 0 (0) |
| Renal failure | 2 (6) | 0 (0) |
| Secondary malignancy* | 2 (6) | 0 (0) |
| Other | 4 (11) | 1 (3) |
| Events . | Subjects affected . | |
|---|---|---|
| Total n (%) . | Treatment-related, n (%) . | |
| Febrile neutropenia | 8 (22) | 4 (11) |
| Infection | 4 (11) | 1 (3) |
| Cardiac (arrhythmia, CHF, vasovagal) | 4 (11) | 1 (3) |
| Pulmonary (pneumonitis, pneumonia) | 4 (11) | 1 (3) |
| Constitutional symptoms | 4 (11) | 1 (3) |
| Dermatologic | 4 (11) | 0 (0) |
| Vascular access-related thrombosis | 2 (6) | 0 (0) |
| Hemorrhage | 2 (6) | 0 (0) |
| Renal failure | 2 (6) | 0 (0) |
| Secondary malignancy* | 2 (6) | 0 (0) |
| Other | 4 (11) | 1 (3) |
CHF indicates congestive heart failure.
Basal cell carcinoma of the left earlobe and squamous cell carcinoma of the skin.